Citations

Clear

1422 citation(s) found for "White, JB".

The Impact of Alcohol in Inflammatory Bowel Diseases
White, Bradley , Ramos, Guilherme Piovezani , Kane, Sunanda V. , White, Bradley A , Kane, S , Ramos, Guilherme P

Mayo Clinic

Inflammatory Bowel Diseases | May 14, 2021 | Volume: 28 | Issue: 3 | Pages: 466-473

10.1093/ibd/izab089 | PMID 33988227 Get It

AbstractSeveral environmental factors have been implicated in the pathogenesis of inflammatory bowel diseases (IBD); however, the evidence for alcohol is sparse, as is its implications on disease activity and overall management. Here, we examine the available evidence for the effect of alcohol on IBD, including its association with the development of IBD, role in exacerbations, and potential medication interactions. Several mechanisms have been demonstrated to mediate the effects of ethanol in the gastrointestinal tract. Alcohol has been shown to alter the gut microbiome, disrupt intestinal barrier, and increase intestinal permeability, directly and indirectly promoting immune activation. Conversely, specific alcoholic beverages, notably red wine, may have anti-inflammatory properties capable of assisting in disease control and affecting disease monitoring. Nonetheless, most alcohol-mediated effects seem to facilitate intestinal inflammation and consequently impact disease onset, recurrence, and symptom control. Furthermore, alcohol use interferes with the metabolism of several medications leading to increased side effect profiles or even loss of effect. Notably, mesalamine, azathioprine, methotrexate, and biologic medications can all be affected by concomitant alcohol intake via a variety of mechanisms.
Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study
Hua, Xinwei , Lindström, Sara , Harrison, Tabitha A. , Alwers, Elizabeth , Berndt, Sonja I. , Brenner, Hermann , Buchanan, Daniel D. , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Goldberg, Richard M. , Gunter, Marc J. , Hoffmeister, Michael , Joshi, Amit D. , Murphy, Neil , Pai, Rish K. , Shi, Qian , Slattery, Martha L. , Song, Mingyang , Peters, Ulrike , Harrison, Tabitha A , Brenner, Hermann , Buchanan, Daniel D , Campbell, Peter T , Chang-Claude, Jenny , Giles, Graham G , Goldberg, Richard M , Hoffmeister, Michael , Milne, Roger L , Pai, R K , Sakoda, Lori C , Schoen, Robert E , Slattery, Martha L , Peters, Ulrike , Gunter, Marc J , Shi, Qian , Murphy, Neil , Song, Mingyang , Dai, James Y. , Lin, Yi , Alberts, Steven R. , Campbell, Peter T. , Giles, Graham G. , Jenkins, Mark A. , Ma, Wenjie , Milne, Roger L. , Sakoda, Lori C. , Schoen, Robert E. , White, Emily E. , Marchand, Loı̈c Le , Chan, Andrew T. , Newcomb, Polly A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 10, 2021 | Volume: 30 | Issue: 7 | Pages: 1349-1358

10.1158/1055-9965.epi-20-1848 | PMID 33972368 Get It

Abstract Background: A positive association between circulating C-reactive protein (CRP) and colorectal cancer survival was reported in observational studies, which are susceptible to unmeasured confounding and reverse causality. We used a Mendelian randomization approach to evaluate the association between genetically predicted CRP concentrations and colorectal cancer–specific survival. Methods: We used individual-level data for 16,918 eligible colorectal cancer cases of European ancestry from 15 studies within the International Survival Analysis of Colorectal Cancer Consortium. We calculated a genetic-risk score based on 52 CRP-associated genetic variants identified from genome-wide association studies. Because of the non-collapsibility of hazard ratios from Cox proportional hazards models, we used the additive hazards model to calculate hazard differences (HD) and 95% confidence intervals (CI) for the association between genetically predicted CRP concentrations and colorectal cancer–specific survival, overall and by stage at diagnosis and tumor location. Analyses were adjusted for age at diagnosis, sex, body mass index, genotyping platform, study, and principal components. Results: Of the 5,395 (32%) deaths accrued over up to 10 years of follow-up, 3,808 (23%) were due to colorectal cancer. Genetically predicted CRP concentration was not associated with colorectal cancer–specific survival (HD, −1.15; 95% CI, −2.76 to 0.47 per 100,000 person-years; P = 0.16). Similarly, no associations were observed in subgroup analyses by stage at diagnosis or tumor location. Conclusions: Despite adequate power to detect moderate associations, our results did not support a causal effect of circulating CRP concentrations on colorectal cancer–specific survival. Impact: Future research evaluating genetically determined levels of other circulating inflammatory biomarkers (i.e., IL6) with colorectal cancer survival outcomes is needed.
Current State of Evidence on Kidney Transplantation: How Fragile Are the Results?
Budhiraja, Pooja , Kaplan, Bruce , Kalot, Mohamad A. , Alayli, Abdallah El , Dimassi, Ahmad , Chakkera, Harini A. , Heilman, Raymond L. , Edwards, Audrene, Heilman, Raymond, Kalot, Mohamad A , Chakkera, Harini A , Budhiraja, Pooja , Mustafa, Reem A

Mayo Clinic

Transplantation | May 10, 2021 | Volume: 106 | Issue: 2 | Pages: 248-256

10.1097/tp.0000000000003805 | PMID 33966022 Get It

Background. The study aims is to use the fragility index (FI) to examine the strength of evidence of randomized controlled trials (RCTs) published in the last decade on kidney transplantation. Methods. We searched MEDLINE for studies on kidney transplantation. We included the RCTs that compared 2 groups with 1:1 randomization and reported significant P values (<0.05) for a dichotomous outcome and were published in the top 10 transplant journals. We calculated the FI; a calculation used to determine the minimum number of subjects needed to change from a nonevent to an event to make the study results nonsignificant (P ≥ 0.05). Results. Fifty-seven RCTs met our inclusion criteria. The median sample size was 100 participants in each arm, the median number of events was 16 (interquartile range, 8–30) in the intervention group. Among the included trials, 79% were industry-funded, 93% involved medications, and the majority were open label. The median FI was 3 (interquartile range, 1–11). In 43% of the trials, the number of patients reported lost to follow-up was higher than or equal to the FI. Only 4% of the RCTs imputed a value for the missing dichotomous outcome. Furthermore, the median number of subjects who discontinued the trial because of adverse effects was 21, which was greater than the FI in 60% of the RCTs. Conclusions. The arbitrary classification of results into “significant” and “nonsignificant” based on P value <0.05 should perhaps be interpreted with the help of other statistical parameters and FI is one of them.
Intracranial Stenting: Angioplasty Basic Technique, Indications, and Sizing: 2-Dimensional Operative Video
Dossani, Rimal H., Cappuzzo, Justin M. , Sonig, Ashish , Siddiqui, Adnan H. , Davies, Jason M. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , Davies, Jason M , Siddiqui, Adnan H , Schirmer, Clemens M , Waqas, Muhammad , Levy, Elad I. , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | May 7, 2021 | Volume: 21 | Issue: 2 | Pages: E115-E116

10.1093/ons/opab124 | PMID 33956956 Get It

Abstract Intracranial atherosclerotic disease (ICAD) is a common cause of stroke. Antiplatelet therapy is the mainstay for symptomatic ICAD treatment. Endovascular management with submaximal angioplasty and/or intracranial stenting is reserved for patients with repeated ischemic events despite optimal medical therapy. We demonstrate intracranial angioplasty and stenting technique, technique indications, and sizing of stent and target vessel diameter. Stenting and angioplasty have been described in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis and Wingspan Stent System Post Market Surveillance trials. 1,2 Submaximal angioplasty has also been described. 3 This patient, who had been on dual antiplatelet therapy for several months, initially presented with occlusion of the left middle cerebral artery M2 inferior division and underwent mechanical thrombectomy with successful reperfusion. Postoperatively, the patient's symptoms did not improve. Medical management was optimized with heparin infusion. However, repeat stroke study demonstrated M2 inferior division reocclusion. A decision was made to proceed with intracranial angioplasty and stenting. P2Y12 levels were therapeutic. Under moderate conscious sedation, submaximal angioplasty of up to 80% of the normal M2 caliber was attempted. However, we observed persistent high-grade stenosis of the M2 inferior division. The major risk of crossing the lesion for angioplasty is vessel perforation. To safely perform this maneuver, we used a J-configured Synchro-2 microwire (Stryker). Because of the patient's recent thrombectomy, we also had prior tactile feedback about how much resistance was encountered while crossing the occlusion. We then deployed a balloon-mounted intracranial stent for optimal radial force across the stenotic area to restore perfusion. Postoperative computed tomography perfusion showed resolution of the previously noticed perfusion deficit. The patient gave informed consent for the procedures and video recording. Institutional review board approval was deemed unnecessary. Video. ©University at Buffalo Neurosurgery, September 2020. With permission.
Detection of a mosaic CDKL5 deletion and inversion by optical genome mapping ends an exhaustive diagnostic odyssey
Cope, Heidi , Barseghyan, Hayk , Bhattacharya, Surajit, Fu, Yulong , Hoppman, Nicole L., Marcou, Cherisse A. , Walley, Nicole, Rehder, Catherine , Deak, Kristen , Alkelai, Anna , Network, Undiagnosed Diseases, Shashi, Vandana , Oglesbee, Devin , Jarvik, Gail P. , McCauley, Jacob L. , Nelson, Stanley F. , Azamian, Mahshid S. , Martínez-Agosto, Julián A. , Chang, Ta Chen , Blue, Elizabeth , Douine, Emilie D. , Woods, Jeremy D. , Baldridge, Dustin , Hoppman, Nicole, Marcou, Cherisse, Oglesbee, Devin , Jarvik, Gail P , Baldridge, Dustin , McCauley, Jacob L , Bhattacharya, Surajit , Walley, Nicole, Network, Undiagnosed Diseases, Vilain, Eric J. N.

Mayo Clinic

Molecular Genetics & Genomic Medicine | May 7, 2021 | Volume: 9 | Issue: 7 | Pages: No page available

10.1002/mgg3.1665 | PMID 33955715 Get It

ABSTRACTBackgroundCurrently available structural variant (SV) detection methods do not span the complete spectrum of disease‐causing SVs. Optical genome mapping (OGM), an emerging technology with the potential to resolve diagnostic dilemmas, was performed to investigate clinically‐relevant SVs in a 4‐year‐old male with an epileptic encephalopathy of undiagnosed molecular origin.MethodsOGM was utilized to image long, megabase‐size DNA molecules, fluorescently labeled at specific sequence motifs throughout the genome with high sensitivity for detection of SVs greater than 500 bp in size. OGM results were confirmed in a CLIA‐certified laboratory via mate‐pair sequencing.ResultsOGM identified a mosaic, de novo 90 kb deletion and inversion on the X chromosome disrupting the CDKL5 gene. Detection of the mosaic deletion, which had been previously undetected by chromosomal microarray, an infantile epilepsy panel including exon‐level microarray for CDKL5, exome sequencing as well as genome sequencing, resulted in a diagnosis of X‐linked dominant early infantile epileptic encephalopathy‐2.ConclusionOGM affords an effective technology for the detection of SVs, especially those that are mosaic, since these remain difficult to detect with current NGS technologies and with conventional chromosomal microarrays. Further research in undiagnosed populations with OGM is warranted.
Impact of stent length and diameter on 10‐year mortality in the SYNTAXES trial
Hara, Hironori , Ono, Masafumi , Kawashima, Hideyuki , Kogame, Norihiro , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Davierwala, Piroze , Mohr, Friedrich W., Thuijs, Daniel J.F.M. , Head, Stuart J., Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Serruys, Patrick W , Onuma, Yoshinobu , Kappetein, A. Pieter , Serruys, Patrick W. , Investigators, for the SYNTAX Extended Survival

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 6, 2021 | Volume: 98 | Issue: 3 | Pages: No page available

10.1002/ccd.29721 | PMID 33951265 Get It

AbstractObjectivesWe investigated the impact of total stent length (TSL) and average nominal stent diameter (ASD) on 10‐year mortality after percutaneous coronary intervention (PCI) in the SYNTAXES trial.BackgroundTSL and ASD in patients treated with PCI are associated with major adverse cardiovascular events. However, the treatment effect of PCI with extensive and/or small stenting as compared with coronary artery bypass grafting (CABG) for complex coronary artery disease has not been fully evaluated.MethodsImpacts on mortality of extensive stenting defined as TSL >100 mm and small stenting as ASD <3 mm were analyzed in 893 PCI patients and were compared to 865 CABG patients.ResultsTSL as a continuous variable was significantly associated with 10‐year mortality (adjusted hazard ratio [HR], 1.05 [1.01–1.09] per 10 mm increase). PCI patients with extensive stenting had a higher 10 year mortality than CABG patients (adjusted HR, 1.97 [1.41–2.74]) or not‐ extensive stenting PCI (adjusted HR, 1.94 [1.36–2.77]). Although ASD did not have a significant association with 10 year mortality (adjusted HR, 0.97 [0.85–1.11] per 0.25 mm increase), PCI with small stents was associated with a higher 10 year mortality, compared to CABG (adjusted HR, 1.66 [1.23–2.26]) and PCI performed with large stents (adjusted HR, 1.74 [1.19–2.53]). Patients treated with not‐extensive and large stents had similar mortality rates (24.0 versus 23.8%) as those treated with CABG.ConclusionsExtensive and small stenting were associated with higher 10 year mortality, compared with CABG. When patients have to be treated with extensive or small stenting, revascularization with CABG should be preferred.
Common Femoral Artery Access: 2-Dimensional Operative Video
Darwal, Maureen A, Binning, Mandy J., Bain, Mark, Bendock, Bernard, Boulos, Alan S. , Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Turner, Raymond D , Welch, Babu G. , White, Jonathan A. , Schirmer, Clemens M , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Lopes, Demetrius K. , Mocco, J , Rodriguez, Rafael, Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Thomas, Ajith J

Mayo Clinic

Operative Neurosurgery | May 4, 2021 | Volume: 19 | Issue: 6 | Pages: E594-E594

10.1093/ons/opaa192 | PMID 34383930 Get It

Abstract Vascular access for cerebral angiography has traditionally been performed via the common femoral artery. It is crucial to obtain safe access to prevent complications that could lead to limb ischemia, groin hematoma, or retroperitoneal hematoma. This is especially true in neurointervention as many patients are anticoagulated or have received intravenous thrombolytics prior to their intervention. Special attention to anatomic landmarks, both grossly and radiographically, can help to assure safe access. The patient consented for this procedure. This video details rapid but safe femoral artery access in a patient undergoing emergent thrombectomy.
Carotid Stenting: Flow Reversal Technique: 2-Dimensional Operative Video
Domingo, Ricardo A. , Ravindran, Krishnan , Tawk, Rabih G. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , Tawk, Rabih G , Schirmer, Clemens M , Domingo, Ricardo A , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | April 30, 2021 | Volume: 21 | Issue: 2 | Pages: E111-E112

10.1093/ons/opab119 | PMID 33929024 Get It

Abstract Management options for carotid stenosis include medical management, carotid endarterectomy, carotid stenting with distal filter protection, or stenting with either flow arrest or flow reversal techniques. 1 Flow reversal with transcarotid artery revascularization (TCAR) technique represents a hybrid approach with surgical access to the common carotid for endovascular placement of a stent in the internal carotid artery. This direct access to the carotid artery avoids navigating the challenging anatomy of the aortic arch with endovascular devices. 2 Compared to transfemoral stenting, TCAR possesses lower risk of transient ischemic attack and stroke, and compared to carotid endarterectomy, there is less risk of cranial neuropathy. 3,4 We present the case of an 87-yr-old man with recurrent severe stenosis (85%) of the right internal carotid artery. The patient had a remote history of bilateral endarterectomies for asymptomatic stenosis and was found with recurrence and progression of right internal carotid artery stenosis. Options were discussed and decision was made to proceed with TCAR after he consented for the procedure. The patient tolerated the procedure well with satisfactory revascularization. Exam remained unremarkable prior to discharge on postoperative day 1 and during follow-up at 1 mo. Patient consented to the publication of their image.
Intracranial Access: Dural Venous Sinus Stenting: 2-Dimensional Operative Video
Domingo, Ricardo A. , Ravindran, Krishnan , Kulakova, Katya, Tawk, Rabih G. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Tawk, Rabih G , Schirmer, Clemens M , Domingo, Ricardo A , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | April 23, 2021 | Volume: 21 | Issue: 2 | Pages: E113-E114

10.1093/ons/opab120 | PMID 33891009 Get It

Abstract Cerebral venous sinus stenting has gained popularity in recent years as a safe and efficacious treatment of selected patients with idiopathic intracranial hypertension (IIH) and focal venous sinus stenosis.1–3 - 3 The main goal of treatment is to prevent visual loss, and often patients report resolution of headache and visual symptoms within 21 mo of mean follow-up.4–8 - 8 We present the case of a 57-yr-old woman with medically refractory IIH, bilateral sinus stenosis, and a mass lesion causing stenosis on the left. Venous angiogram with pressure monitoring was completed with the patient awake, which showed a significant pressure gradient on the right (19 mm Hg) and borderline gradient on the left (8 mm Hg). Options were reviewed and decision was made to proceed with the treatment of the right-sided stenosis with stenting and continue with the observation of the lesion on the left to prevent further visual deterioration. The patient consented for the procedure, and she tolerated the procedure well. Neurological exam remained at baseline, and she was discharged home on post-operative day #1. At 2 mo’s follow-up, the patient reported improvement in headaches and remained intact neurologically.